CRDF Stock Cardiff Oncology, Inc.
US · NasdaqCMLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Cardiovascular pipeline milestones could materially re-rate the company if clinical results remain favorable.
Signal breakdown
- ▸Consensus Strong Buy with a $10 target.
- ▾Below 50-day MA (-14.45%)
- ▾Near 52-week low (6.7% of range)
Is CRDF a buy right now?
Trend: CRDF is trading below the 50-day average (-25.93%), RSI 60 — neutral momentum, with a 3-month return of -2.44%.
Valuation & quality: Cardiff Oncology, Inc. trades on forward P/E -1.5, price-to-book 2.08; fundamentals show net margin 0.0%, return on equity -94.1%, revenue growth -14.1% year on year.
Analyst consensus: 6 analysts have a mean 12-month price target of $6.28 (+681.2% vs the last close; range $1.20 – $12.00), consensus rating “none”.
Our screen: WATCH (score 0) — Cardiovascular pipeline milestones could materially re-rate the company if clinical results remain favorable.
Computed from end-of-day data; not personal advice.
Our track record with CRDF
First flagged in our daily picks as WATCH on 2026-10-21 at $0.93 — -13.7% since.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -16.50% | +6.80% | +9.80% | -31.60% | -33.80% | +15.10% | +22.20% | -33.90% |
Fundamentals
Analyst price target
Technical signals
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Sector: Healthcare · Industry: Biotechnology · United States · 30 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.